Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald L Krall

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Lancet (London, England)|June 19, 2007
Cardiovascular safety of rosiglitazoneRonald L Krall
The New England Journal of Medicine|October 31, 2007
Rosiglitazone and the FDARonald L Krall
The New England Journal of Medicine|April 1, 2006
Clinical trials report cardRonald L Krall, Frank Rockhold
Journal of the Royal Society of Medicine|September 2, 2006
Reasons for optimism not disillusionmentRonald L Krall, Frank Rockhold
Plos Medicine|April 7, 2007
Clinical trials registrationFrank W Rockhold, Ronald L Krall
Lancet (London, England)|May 23, 2006
Trial summaries on results databases and journal publicationFrank W Rockhold, Ronald L Krall
Bipolar Disorders|June 20, 2018
Comprehensive comparison of monotherapies for psychiatric hospitalization risk in bipolar disordersAnastasiya Nestsiarovich, Aurélien J Mazurie, Nathaniel G Hurwitz, et al.
Nature Biotechnology|May 31, 2003
Making 'safety first' a reality for biotechnology productsAnne R Kapuscinski, Robert M Goodman, Stuart D Hann, et al.
JMIR Mental Health|June 26, 2019
Preferences of Information Dissemination on Treatment for Bipolar Disorder: Patient-Centered Focus Group StudyBerit Kerner, Annette S Crisanti, Jason L DeShaw, et al.
Bipolar Disorders|September 14, 2017
Systemic challenges in bipolar disorder management: A patient-centered approachAnastasiya Nestsiarovich, Nathaniel G Hurwitz, Stuart J Nelson, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Lancet (London, England)|June 19, 2007
Cardiovascular safety of rosiglitazoneRonald L Krall
The New England Journal of Medicine|October 31, 2007
Rosiglitazone and the FDARonald L Krall
The New England Journal of Medicine|April 1, 2006
Clinical trials report cardRonald L Krall, Frank Rockhold
Journal of the Royal Society of Medicine|September 2, 2006
Reasons for optimism not disillusionmentRonald L Krall, Frank Rockhold
Plos Medicine|April 7, 2007
Clinical trials registrationFrank W Rockhold, Ronald L Krall
Lancet (London, England)|May 23, 2006
Trial summaries on results databases and journal publicationFrank W Rockhold, Ronald L Krall
Bipolar Disorders|June 20, 2018
Comprehensive comparison of monotherapies for psychiatric hospitalization risk in bipolar disordersAnastasiya Nestsiarovich, Aurélien J Mazurie, Nathaniel G Hurwitz, et al.
Nature Biotechnology|May 31, 2003
Making 'safety first' a reality for biotechnology productsAnne R Kapuscinski, Robert M Goodman, Stuart D Hann, et al.
JMIR Mental Health|June 26, 2019
Preferences of Information Dissemination on Treatment for Bipolar Disorder: Patient-Centered Focus Group StudyBerit Kerner, Annette S Crisanti, Jason L DeShaw, et al.
Bipolar Disorders|September 14, 2017
Systemic challenges in bipolar disorder management: A patient-centered approachAnastasiya Nestsiarovich, Nathaniel G Hurwitz, Stuart J Nelson, et al.
Pageof 1